Literature DB >> 7820664

Potentially amyloidogenic fragment of 50 kDa and intracellular processing of amyloid precursor protein in cells cultured under leupeptin.

K Tsuzuki1, R Fukatsu, Y Takamaru, N Fujii, N Takahata.   

Abstract

The principal neuropathological feature of Alzheimer's disease is extracellular deposition of approximately 4-kDa proteinous fragment, designated as beta-amyloid peptides (beta/A4 peptides) derived by proteolytic cleavage from amyloid precursor protein (APP), a large cell-surface receptor-like protein. There has been evidence that APP is proteolytically degraded in the secretory and endosomal/lysosomal pathways. The pathway in which APP is cleaved to generate beta/A4 peptides is still not identified. To clarify the intracellular processing of APP into the generation of beta/A4 peptides, we detected and characterized potentially amyloidogenic or non-amyloidogenic fragments using newly established monoclonal and polyclonal antibodies in the cultured cells with or without leupeptin, potent lysosomal protease inhibitor of lysosome. APP fragments of 50 and 20 kDa containing full-length beta/A4 peptides were identified in the cultured cells. Immunoblot analysis, biochemical study for specific marker enzyme activity of the fractions obtained from subcellular fractionation, sucrose density gradient centrifugation indicated that the 50-kDa APP fragment was produced in the compartment closely related to endosomal/lysosomal system. Our data suggest that the endosomal/lysosomal pathway is involved in the processing and generation of beta/A4 peptides.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7820664     DOI: 10.1016/0006-8993(94)90881-8

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  3 in total

1.  Beta-amyloid protein-containing inclusions in skeletal muscle of apolipoprotein-E-deficient mice.

Authors:  T A Robertson; N S Dutton; R N Martins; A D Roses; B A Kakulas; J M Papadimitriou
Journal:  Am J Pathol       Date:  1997-02       Impact factor: 4.307

2.  Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases.

Authors:  N Sasaki; R Fukatsu; K Tsuzuki; Y Hayashi; T Yoshida; N Fujii; T Koike; I Wakayama; R Yanagihara; R Garruto; N Amano; Z Makita
Journal:  Am J Pathol       Date:  1998-10       Impact factor: 4.307

3.  Conformational altered p53 affects neuronal function: relevance for the response to toxic insult and growth-associated protein 43 expression.

Authors:  L Buizza; C Prandelli; S A Bonini; A Delbarba; G Cenini; C Lanni; E Buoso; M Racchi; S Govoni; M Memo; D Uberti
Journal:  Cell Death Dis       Date:  2013-02-07       Impact factor: 8.469

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.